Shots:
- Sino Biopharm via its subsidiary Chia Tai Tianqing has entered into an exclusive license agreement with a fully owned subsidiary of Sanofi for rovadicitinib
- As per the deal, Sanofi will obtain exclusive global license to develop, manufacture & commercialize rovadicitinib in exchange for $135M upfront & ~$1.395B in development, regulatory & sales milestones, as well as up to double-digit net sales-based tiered royalties
- Rovadicitnib (PO) is a dual JAK/ROCK inhibitor that blocks the JAK/STAT pathway to reduce cytokine production & inhibits ROCK-mediated STAT3/5 signaling to suppress Th17 cells & enhance Treg activity, restoring immune balance
Ref: Sino | Image: Sino & Sanofi | Press Release
Related News: The US FDA Approves Regeneron and Sanofi’s Dupixent for Allergic Fungal Rhinosinusitis (AFRS)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
